NCT02182505View on ClinicalTrials.gov

Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

535

Participants

Timeline

Start Date

September 30, 1998

Primary Completion Date

July 31, 1999

Conditions
Asthma
Interventions
DRUG

Berodual® Respimat®, low dose

DRUG

Berodual® Respimat®, high dose

DRUG

Berodual® MDI

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY